Oric Pharmaceuticals, Inc. (ORIC) stock
ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.65−0.35 (-4.37%)
Close on Nov 18, 2026Market cap $792.94MP/E –Yield –
Oric Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
Oric Pharmaceuticals's net income for the twelve months ending Jun 30, 2026 was -$140.35M. For fiscal 2025 it was -$129.47M. The highest annual figure on record is -$21.36M in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$129.47M | – |
| FY2024 | Dec 31, 2024 | -$127.85M | – |
| FY2023 | Dec 31, 2023 | -$100.70M | – |
| FY2022 | Dec 31, 2022 | -$89.12M | – |
| FY2021 | Dec 31, 2021 | -$78.72M | – |
| FY2020 | Dec 31, 2020 | -$73.70M | – |
| FY2019 | Dec 31, 2019 | -$26.88M | – |
| FY2018 | Dec 31, 2018 | -$21.36M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$41.49M | – |
| Q1 FY2026 | Mar 31, 2026 | -$35.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$31.96M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$25.48M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.94M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.83M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.77M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$21.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.51M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.26M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.55M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.02M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.87M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.97M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.02M | – |
See a number that looks wrong?